AbbVie
ABBV
ABBV
3,043 hedge funds and large institutions have $195B invested in AbbVie in 2022 Q1 according to their latest regulatory filings, with 234 funds opening new positions, 1,152 increasing their positions, 1,327 reducing their positions, and 124 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
8% more call options, than puts
Call options by funds: $3.37B | Put options by funds: $3.13B
0.97% more ownership
Funds ownership: 67.35% → 68.32% (+0.97%)
13% less repeat investments, than reductions
Existing positions increased: 1,152 | Existing positions reduced: 1,327
Holders
3,043
Holding in Top 10
296
Calls
$3.37B
Puts
$3.13B
Top Buyers
| 1 | +$3.06B | |
| 2 | +$1.78B | |
| 3 | +$682M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$672M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$611M |
Top Sellers
| 1 | -$916M | |
| 2 | -$411M | |
| 3 | -$345M | |
| 4 |
Bank of New York Mellon
New York
|
-$256M |
| 5 |
Barclays
London,
United Kingdom
|
-$235M |